Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVSNASDAQ:EVFMNASDAQ:OGINASDAQ:PRQR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$3.04+15.2%$2.10$1.11▼$17.88$51.44M1.62744,975 shs799,939 shsEVFMEvofem Biosciences$0.01-4.0%$0.01$0.01▼$0.02$1.14M-1.01447,081 shs41,189 shsOGIOrganigram Global$1.36+6.3%$1.25$0.85▼$2.08$171.44M1.37660,427 shs632,887 shsPRQRProQR Therapeutics$2.03+4.1%$1.66$1.07▼$4.62$205.16M0.31644,770 shs255,122 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio+1.07%-5.95%+32.66%+34.69%-55.56%EVFMEvofem Biosciences+3.09%+7.53%+1.01%+16.28%-4.76%OGIOrganigram Global-0.78%-10.49%-6.57%+19.63%-16.07%PRQRProQR Therapeutics+1.04%+2.63%+16.77%+21.12%+14.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANVSAnnovis Bio2.3716 of 5 stars3.51.00.00.03.21.70.6EVFMEvofem Biosciences0.566 of 5 stars0.03.00.04.80.00.00.0OGIOrganigram Global0.6272 of 5 stars0.01.00.00.01.10.02.5PRQRProQR Therapeutics1.2676 of 5 stars3.63.00.00.00.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 3.00Buy$30.25895.07% UpsideEVFMEvofem Biosciences 0.00N/AN/AN/AOGIOrganigram Global 3.00BuyN/AN/APRQRProQR Therapeutics 3.13Buy$8.00294.09% UpsideCurrent Analyst Ratings BreakdownLatest EVFM, OGI, ANVS, and PRQR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $12.005/15/2025ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $17.005/13/2025PRQRProQR TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $9.004/29/2025PRQRProQR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$8.004/29/2025PRQRProQR TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A$0.67 per shareN/AEVFMEvofem Biosciences$11.39M0.10N/AN/A($2.64) per share0.00OGIOrganigram Global$117.47M1.55N/AN/A$2.07 per share0.66PRQRProQR Therapeutics$20.46M10.44N/AN/A$0.91 per share2.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$24.59M-$2.16N/AN/AN/AN/A-300.56%-193.50%8/13/2025 (Estimated)EVFMEvofem Biosciences$52.98M-$0.05N/A∞N/A-46.42%-91.97%-61.93%N/AOGIOrganigram Global-$33.39M$0.1013.60N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)PRQRProQR Therapeutics-$30.04M-$0.35N/AN/AN/A-157.04%-53.49%-22.07%8/4/2025 (Estimated)Latest EVFM, OGI, ANVS, and PRQR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ANVSAnnovis Bio-$0.47-$0.32+$0.15-$0.32N/AN/A5/8/2025Q1 2025PRQRProQR Therapeutics-$0.09-$0.1082-$0.0182-$0.11$4.90 million$4.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A10.6810.68EVFMEvofem BiosciencesN/A0.110.09OGIOrganigram GlobalN/A3.421.90PRQRProQR TherapeuticsN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%EVFMEvofem Biosciences0.22%OGIOrganigram Global34.63%PRQRProQR Therapeutics32.65%Insider OwnershipCompanyInsider OwnershipANVSAnnovis Bio20.80%EVFMEvofem Biosciences0.21%OGIOrganigram Global0.09%PRQRProQR Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio319.49 million15.43 millionOptionableEVFMEvofem Biosciences120118.66 million113.12 millionNot OptionableOGIOrganigram Global860133.94 million133.82 millionOptionablePRQRProQR Therapeutics180105.21 million96.38 millionOptionableEVFM, OGI, ANVS, and PRQR HeadlinesRecent News About These CompaniesCantor Fitzgerald Comments on PRQR FY2026 EarningsJune 10, 2025 | marketbeat.comTwo Sigma Investments LP Buys 320,614 Shares of ProQR Therapeutics (NASDAQ:PRQR)June 6, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of "Buy" by AnalystsJune 5, 2025 | marketbeat.comProQR Therapeutics Reports Q1 2025 Financial ResultsJune 3, 2025 | tipranks.comProQR Therapeutics (NASDAQ:PRQR) Short Interest Up 50.9% in MayJune 2, 2025 | marketbeat.comNorthern Trust Corp Has $1.11 Million Stock Holdings in ProQR Therapeutics (NASDAQ:PRQR)May 30, 2025 | marketbeat.comMillennium Management LLC Buys 2,683,351 Shares of ProQR Therapeutics (NASDAQ:PRQR)May 28, 2025 | marketbeat.comWoodline Partners LP Buys Shares of 3,557,001 ProQR Therapeutics (NASDAQ:PRQR)May 25, 2025 | marketbeat.comProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal yearMay 24, 2025 | investing.comProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock NewsMay 13, 2025 | gurufocus.comProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES ConferencesMay 12, 2025 | globenewswire.comProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial PositionMay 10, 2025 | nasdaq.comProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial ResultsMay 10, 2025 | finanznachrichten.deProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial ResultsMay 10, 2025 | finanznachrichten.deNew Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)May 10, 2025 | finance.yahoo.comProQR: Q1 Earnings SnapshotMay 10, 2025 | finance.yahoo.comProQR: Q1 Earnings SnapshotMay 10, 2025 | finance.yahoo.comProQR Announces First Quarter 2025 Operating and Financial ResultsMay 8, 2025 | globenewswire.comProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences ConferenceMay 2, 2025 | globenewswire.comProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025May 1, 2025 | globenewswire.comProQR Therapeutics initiated with an Outperform at Evercore ISIApril 30, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeAnalysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernSoFi Stock’s Next Test: Can It Justify Its Premium Valuation?By Chris Markoch | June 13, 2025View SoFi Stock’s Next Test: Can It Justify Its Premium Valuation?Wall Street Sees More Upside for Dell and HPEBy Leo Miller | June 12, 2025View Wall Street Sees More Upside for Dell and HPEGeospace Stock Skyrockets After Major Petrobras ContractBy Jeffrey Neal Johnson | June 24, 2025View Geospace Stock Skyrockets After Major Petrobras ContractEVFM, OGI, ANVS, and PRQR Company DescriptionsAnnovis Bio NYSE:ANVS$3.04 +0.40 (+15.15%) Closing price 03:59 PM EasternExtended Trading$2.95 -0.09 (-2.96%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Evofem Biosciences NASDAQ:EVFM$0.0096 0.00 (-4.00%) As of 03:55 PM EasternEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.Organigram Global NASDAQ:OGI$1.36 +0.08 (+6.25%) Closing price 04:00 PM EasternExtended Trading$1.36 -0.01 (-0.37%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.ProQR Therapeutics NASDAQ:PRQR$2.03 +0.08 (+4.10%) Closing price 04:00 PM EasternExtended Trading$2.02 0.00 (-0.25%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
